Research programme: biodefence anti-infectives - Microbiotix

Drug Profile

Research programme: biodefence anti-infectives - Microbiotix

Alternative Names: Yersinia pestis cell surface plasminogen activator inhibitors - Microbiotix; Biodefence DNA helicase inhibitors - Microbiotix; Biodefence DNA replicase inhibitors - Microbiotix; Biodefense anti-infectives - Microbiotix; Quinolone-based inhibitors of BoNT/A LC - Microbiotix

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Microbiotix
  • Class Imidazolines; Indoles; Nucleosides; Quinolones; Small molecules
  • Mechanism of Action Adenosylhomocysteinase inhibitors; Botulinum toxin inhibitors; DNA helicase inhibitors; DNA helicase-primase inhibitors; DNA topoisomerase IV inhibitors; DNA-directed DNA polymerase inhibitors; Metalloprotease inhibitors; Plasminogen activator inhibitors; Toll-like receptor 5 antagonists; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Anthrax; Botulism; Burkholderia infections; Ebola virus infections; Gram-negative infections; Yersinia infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Anthrax in USA
  • 04 Nov 2017 No recent reports of development identified for research development in Botulism in USA
  • 04 Nov 2017 No recent reports of development identified for research development in Burkholderia infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top